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New cancer therapies are being developed that trigger tumour apoptosis and an in vivo method of apoptotic detection and early
treatment response would be of great value. Magnetic resonance spectroscopy (MRS) can determine the tumour biochemical profile
in vivo, and we have investigated whether a specific spectroscopic signature exists for apoptosis in human astrocytomas. High-
resolution magic angle spinning (HRMAS)
1H MRS provided detailed
1H spectra of brain tumour biopsies for direct correlation with
histopathology. Metabolites, mobile lipids and macromolecules were quantified from presaturation HRMAS
1H spectra acquired from
41 biopsies of grades II (n¼8), III (n¼3) and IV (n¼30) astrocytomas. Subsequently, TUNEL and H&E staining provided
quantification of apoptosis, cell density and necrosis. Taurine was found to significantly correlate with apoptotic cell density (TUNEL)
in both non-necrotic (R¼0.727, P¼0.003) and necrotic (R¼0.626, P¼0.0005) biopsies. However, the ca 2.8p.p.m.
polyunsaturated fatty acid peak, observed in other studies as a marker of apoptosis, correlated only in non-necrotic biopsies
(R¼0.705, Po0.005). We suggest that the taurine
1H MRS signal in astrocytomas may be a robust apoptotic biomarker that is
independent of tumour necrotic status.
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Apoptosis is a form of programmed cell death by which an
organism can rid itself of damaged or unwanted cells. Neoplastic
cells are accumulated by increased cellular proliferation and
decreased cellular turnover, and there is much evidence that
apoptosis is inhibited in cancer (Kaufmann and Gores, 2000). Such
changes are due to multiple genetic aberrations and several have
been shown to promote the aggressive characteristics of high-
grade tumours (Rao and James, 2004). Dysregulation of apoptosis-
regulating proteins in cancer provide targets for drug discovery
and new approaches to cancer treatment. If the outcome of a new
treatment is to increase apoptosis, a method for monitoring
apoptosis in vivo for the early detection of drug response would be
of great value. One such modality is magnetic resonance spectro-
scopy (MRS), which can be used to non-invasively determine the
biochemical changes in tumour tissue following treatment.
Drug-induced apoptosis studies have shown good correlations
between apoptosis and nuclear magnetic resonance (NMR) visible
mobile lipids and cytosolic lipid bodies in various human cancer
cell lines: DU145 prostatic carcinoma cells (Milkevitch et al, 2005),
Jurkat T-lymphoblast cells (Di Vito et al, 2001; Al-Saffar et al,
2002) and HuT 78 lymphoblastoid cells (Iorio et al, 2003),
suggesting that MRS-detectable lipids accumulate in tumour cells
undergoing apoptosis. In vivo studies of rodent tumour models
have also shown that drug-induced apoptosis results in the
accumulation of lipids and specifically polyunsaturated fatty acid
(PUFA) resonances at ca. 5.4 and 2.8p.p.m. (Hakuma ¨ki et al, 1999;
Griffin et al, 2003; Schmitz et al, 2005). Lipid droplet production
appears to occur during both apoptotic and necrotic cell death,
and so has been described as a general indicator of cell stress and
death (Delikatny et al, 2002).
High-resolution magic angle spinning (HRMAS) NMR allows
high-resolution spectra to be obtained directly from biopsy tissue,
with the added advantage that the same tissue samples can be
retrieved post-HRMAS for subsequent histological analysis, there-
by allowing a direct comparison between the biochemical and
histological profiles (Wu et al, 2003; Opstad et al, 2008a). In this
study, we have used the terminal deoxynucleotidyl transferase
biotin-dUTP nick end labelling (TUNEL) method for apoptotic cell
detection (Gavrieli et al, 1992) in post-HRMAS tissue and
compared the estimated metabolite concentrations with the
number of TUNEL-positive nuclei per mm
2 in each biopsy across
different grades of glioma. Our aim is to determine a biochemical
correlation to apoptosis in gliomas that could provide a robust
surrogate marker for apoptosis with in vivo MRS.
MATERIALS AND METHODS
Tissue collection
Biopsies were collected during routine surgical resection of 41
adult human gliomas, and histology revealed eight astrocytoma
grade II (AS2), three astrocytoma grade III (AS3) and 30
glioblastoma (GBM) tumours. All patients were untreated for the
tumour, other than dexamethasone, before surgery. Biopsies were
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ssnap-frozen in liquid N2 and subsequently stored at  801C. This
study was performed with the written informed consent of the
entire patients and with the approval from the local ethics
committee.
1H HRMAS spectroscopy
A 10–15mg sample of biopsy tissue was dissected on cardice and
placed in a 50ml insert (Bruker Biospin Limited, Coventry, UK).
The remaining space was then filled with deuterium oxide on ice to
maintain the biopsy temperature below 41C, thus minimising
biochemical changes. The insert was then placed in a 4-mm
zirconium MAS rotor (Bruker Biospin Limited) and the rotor
transferred to the HRMAS probe, which had been precooled to
41C. Measurements were performed on a 600-MHz Bruker Avance
spectrometer, equipped with a quadruple nuclei (
1H,
2H,
13C
and
31P) HRMAS probe, with biopsy samples spun at 5kHz and
maintained at 41C by a Bruker variable temperature unit.
Presaturation spectra were acquired from each biopsy using a
repetition time of E8s, with a total acquisition time of 10min and
57s. A corresponding spectrum without presaturation was also
acquired to obtain a water signal reference.
Spectral quantification
Each brain tumour biopsy presaturation spectrum was analysed
using LCModel (Version 6.1-4) with a presaturation basis set
containing 23 metabolite spectra (acetate, alanine, aspartate,
choline, creatine, g-aminobutyric acid, glucose, glutamine, gluta-
mate, glutathione, glycine, glycerophosphocholine, lactate, leucine,
lysine, myo-inositol, N-acetyl aspartate (NAA), NAA-glutamate,
phosphocholine, phosphoethanolamine, scyllo-inositol, taurine
and valine) and 18 simulated lipid/macromolecule (Lip/MM)
peaks (Opstad et al, 2008b). The metabolite concentrations and
Lip/MM proton concentrations were determined using the biopsy
water signal as a reference, assuming a water concentration of 44 M
(Usenius et al, 1994; Cheng et al, 1998), with no corrections made
for T1 or T2 relaxation, and therefore all concentrations are
expressed semiquantitatively.
Histology
Following HRMAS, each biopsy sample was removed from its
insert, surrounded by optimum cutting temperature (OCT)-
embedding compound (Brights Instrument Co., Huntingdon,
UK) and refrozen on cardice for cryostat sectioning. Biopsies
were sectioned at 10mm and arranged on polysine microscope
slides (VWR International, Lutterworth, UK), so that each slide
had five sections representative of the entire length of the biopsy
for subsequent analysis.
Terminal deoxynucleotidyl transferase biotin-dUTP nick
end labelling staining
The TUNEL method (Gavrieli et al, 1992) was used to stain one
slide from each biopsy using a commercially available TUNEL-
staining kit (Roche Diagnostics Ltd, Burgess Hill, UK). The first
biopsy section on each slide was used as a positive or negative
control, as recommended by the manufacturer’s instructions. It
has previously been reported that TUNEL can label necrotic cells
as well as apoptotic cells (Gold et al, 1994). However, necrotic
areas were clearly visible and showed little, if any, TUNEL-positive
nuclei. The TUNEL-positive nuclei were manually counted for the
remaining four sections of each biopsy slide using an Olympus
BX51 microscope (Olympus Optical Co. Ltd, London, UK).
Composite histological images of each section were captured at
 4 magnification, using a digital camera (ColorView 12, Soft
Imaging System GmbH, Germany), with the aid of a motorised
scanning stage (Prior Scientific Instruments Ltd, Cambridge, UK),
and biopsy section areas were determined by analySIS auto
software (Soft Imaging System, Munster, Germany). Subsequently,
the areas were used to determine the number of TUNEL-positive
nuclei per mm
2 for each biopsy.
Haematoxylin & eosin (H&E)
Harris’ H&E (Sigma-Aldrich, Poole, UK) staining was performed
on a consecutive slide per biopsy for morphological determination.
Composite histological images were captured at  10 magnifica-
tion using the same equipment as before, and the analySIS auto
software (Soft Imaging System) used to determine cell density per
biopsy by thresholding for the haematoxylin-stained nuclei and
expressing as total nuclei per mm
2. Percentage necrosis was also
calculated for each biopsy by measuring the total area of each
biopsy section and their necrotic regions of interest.
RESULTS
Histological analysis of the H&E-stained sections indicated that
necrosis was present in 27/41 biopsies (Table 1). For subsequent
data analyses, the biopsies were divided into two groups: (i) non-
necrotic and (ii) necrotic, according to whether there was a
measurable percentage of necrosis. Figure 1 shows TUNEL-
staining histology in a post-HRMAS non-necrotic biopsy sample.
The TUNEL-positive nuclei are clearly visible (dark stained nuclei)
over the background staining.
Linear regression analysis, with Bonferroni correction for
multiple comparisons, was used to determine which
1H MRS
metabolite and lipid concentrations significantly correlated with
Table 1 Relationship between the necrotic status of the individual
HRMAS tumour biopsies and the grade of the originating tumour as
histopathologically diagnosed from multiple biopsies during surgical excision
Diagnosed grade of originating tumour
Biopsy status AS2 AS3 GBM Total
Non-necrotic 7 2 5 14
Necrotic 1 1 25 27
Total 8 3 30 41
50 M
Figure 1 TUNEL-stained nuclei (dark staining) in a post-HRMAS non-
necrotic astrocytoma biopsy sample.
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sthe apoptotic cell density (TUNEL-stained positive nuclei per
mm
2). Taurine was the only metabolite to significantly correlate
with the TUNEL-stained nuclei in both non-necrotic (R¼0.727,
P¼0.003, n¼14) and necrotic (R¼0.626, P¼0.0005, n¼27)
biopsies, as shown in Figure 2. The slope of the correlation
between taurine and the density of apoptotic cells was similar for
both groups (non-necrotic and necrotic), with both intercepting
very close to the origin. In the non-necrotic biopsies, significant
positive correlations were also found between the number of
apoptotic cells and the ca. 2.8 and 1.3p.p.m. Lip/MM (Table 2 and
Figure 3A and B). A near significant positive correlation was also
found between apoptosis and the ca. 0.9p.p.m. Lip/MM (Table 2
and Figure 3B). However, the necrotic biopsies showed non-
significant negative correlations between the apoptotic cell density
and the ca. 2.8, 1.3 and 0.9p.p.m. Lip/MM (Figure 3A for the ca
2.8p.p.m. Lip/MM; ca.1.3 and 0.9p.p.m. Lip/MM; data not shown).
In the non-necrotic biopsy group, the correlation of apoptotic cell
density with the ca. 2.8p.p.m. Lip/MM also intercepted close to the
origin (Figure 3A), similar to the correlation with taurine
(Figure 2), but this was not true for the correlation of apoptosis
with the ca. 1.3 and 0.9p.p.m. Lip/MM (Figure 3B). Figure 4 shows
example for HRMAS spectra of a non-necrotic (top spectrum) and
necrotic (middle spectrum) biopsy, highlighting the taurine and
ca. 2.8p.p.m. contributions. The taurine concentrations in both
spectra were the same (1.041 and 1.042mM, respectively), but this
figure clearly shows a greater concentration of the ca. 2.8p.p.m.
Lip/MM in the necrotic spectrum (middle spectrum). The
percentage of necrosis in this biopsy was 8.8%.
Cell density and necrosis
Two of the twenty-seven necrotic biopsies had poor H&E staining
that prevented accurate measurement of the cell density and
percentage of necrosis, so these two specimens were excluded from
Figure 5. In Figure 5, the apoptotic cell density was shown to be
independent of the total cell density in the non-necrotic biopsies.
An apparent correlation of apoptotic cell density with total cell
density was found in the necrotic biopsy group (Figure 5), but this
was an artefact of the effect of necrotic dilution on both the
apoptotic and total cell counts per mm
2. Similar results were found
with the correlation between cell density and taurine concentra-
tions in both biopsy groups (data not shown). Although cell
density was found to have a strong negative correlation with the
percentage of necrosis in the necrotic biopsy group (R¼ 0.917,
P¼o0.0001, n¼25), no significant differences were found
between the biopsy groups (non-necrotic and necrotic) in cell
density, number of TUNEL-positive nuclei per mm
2 or taurine
concentrations. In contrast, the ca. 2.8, 1.3 and 0.9p.p.m. Lip/MM
proton concentrations were all significantly different between the
two biopsy groups (P¼o0.0001, P¼o0.0001 and P¼0.01
respectively, Mann–Whitney U-test).
2.5 2.0 1.5 1.0
Taurine (mM)
0.5 0.0
0
50
100
150
200
250
300
T
U
N
E
L
-
p
o
s
i
t
i
v
e
 
n
u
c
l
e
i
 
/
 
m
m
2
Figure 2 Plots and linear regression analyses (±95% confidence limits)
of TUNEL-positive nuclei per mm
2 against taurine concentration (mM) for
non-necrotic (closed symbols and solid lines, R¼0.727, P¼0.003, n¼14)
and necrotic astrocytoma biopsies (open symbols and dashed lines,
R¼0.626, P¼0.0005, n¼27).
Table 2 Correlations of HRMAS
1H MRS metabolite and lipid
concentrations with TUNEL-positive nuclei per mm
2 for non-necrotic
astrocytoma biopsies
Metabolite RP -value
Tau 0.727 0.003*
ca. 2.8p.p.m. 0.705 o0.005*
ca. 1.3p.p.m. 0.703 o0.005*
ca. 0.9p.p.m. 0.676 0.008
*Correlations are significant at P¼0.005 after Bonferroni correction for multiple
comparisons.
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Figure 3 Plots and linear regression analyses (±95% confidence limits)
of TUNEL-positive nuclei per mm
2 against (A) ca. 2.8p.p.m. Lip/MM
proton concentration for non-necrotic (closed symbols and solid lines,
R¼0.705, Po0.005) and necrotic astrocytoma biopsies (open symbols and
dotted line showing the insignificant negative correlation); and (B) ca.
1.3p.p.m. (closed symbols and solid line, R¼0.703, Po0.005) and ca.
0.9p.p.m. Lip/MM proton concentrations (open symbols and dashed line,
R¼0.676, P¼0.008) for the non-necrotic biopsies only.
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sDISCUSSION
The two important findings of this study are (i) taurine
concentration in glioma biopsies is correlated with the number
of TUNEL-stained apoptotic cells (Figure 2) independently of the
presence of necrosis; and (ii) the ca 2.8p.p.m. Lip/MM peak from
PUFAs is correlated with the number of TUNEL-stained apoptotic
cells, but only in the non-necrotic biopsies. Thus, we have found
two potential biomarkers for the in vivo determination of
apoptosis in gliomas.
Taurine has been implicated in the mechanism of cell shrinkage
during apoptosis in several cell types (cerebellar granule neurons,
NIH 3T3 fibroblasts and Jurkat T-lymphocytes (Lang et al, 2000;
Mora ´n et al, 2000; Friis et al, 2005)). Cell shrinkage is a distinctive
characteristic of apoptotic cells, with changes in ion channel fluxes
thought to play a major part (Go ´mez-Angelats and Cidlowski,
2002). However, the exact mechanism of this is unclear. One study
has implicated p38 mitogen-activated protein kinase activation
before an efflux of potassium and taurine from the cell, resulting in
stimulation of the cysteine protease caspase-3 in NIH 3T3
fibroblasts (Friis et al, 2005). Another study has implied that
CD95-receptor triggering leads to a caspase-dependent stimulation
of cellular taurine release, thereby facilitating apoptotic DNA
fragmentation (labelled by the TUNEL reaction (Watanabe et al,
2002)) and cell shrinkage in Jurkat T-lymphocytes (Lang et al,
2000). Whether taurine accumulation occurs only in relation to
apoptotic cells, or whether apoptosis and increased taurine content
derive from a common cause such as hypoxia, resulting in a
population of cells with increased taurine of which some are in the
apoptotic stage, is as yet unknown. Further study is now needed to
understand the processes that give rise to the correlation between
apoptosis and taurine in gliomas as shown in Figure 2.
Necrosis is one of the histopathological indicators of malignancy
in astrocytomas, and Table 1 highlights a discrepancy in a few
tumours between their clinical grading and the presence of
necrosis in the HRMAS biopsy specimens used in this study. This
is likely a result of sampling error and the heterogeneity of
astrocytomas, and does not affect the interpretation of our results
that show direct correlation of the HRMAS data with histopatho-
logical analysis of the same piece of tissue. The presence of
significant amounts of necrosis (or large variations in cell density)
can also produce false correlations between any two parameters
whose value is dependent on the number of viable cells. In
Figure 5, the number of TUNEL-positive nuclei per mm
2 is shown
to correlate with the total biopsy cell density when all the necrotic
biopsies were included in the analysis, but this was because of the
six biopsies (plotted as small open triangles) that had a percentage
necrosis of greater than 50%, and hence very low TUNEL-staining.
However, by treating those samples as outliers and comparing only
the samples with o25% necrosis, it can be seen that there is no
correlation between the number of TUNEL-positive cells per
biopsy sample and cell density. Thus, our result of a correlation
between taurine and TUNEL-staining is a true correlation
independent of cell density or necrosis, when the highly necrotic
samples are excluded.
The ca. 2.8p.p.m. PUFA
1H MRS lipid peak has been previously
assigned as a biomarker of apoptotic response in a study of
anticancer treatment by gene therapy in preclinical rodent gliomas
(Hakuma ¨ki et al, 1999; Griffin et al, 2003) and also proposed as an
in vivo biomarker for apoptosis in the clinic (Hakuma ¨ki et al, 1999;
Schmitz et al, 2005). We also observed a good correlation between
the ca. 2.8p.p.m. (-CH¼CHCH2CH¼CH-) PUFA proton concen-
trations and the number of TUNEL-stained apoptotic nuclei in
human glial brain tumour biopsies, but only in the non-necrotic
biopsies with an intercept close to the origin (Table 2 and
Figure 3A). This suggests that the PUFA peak at ca. 2.8p.p.m.
originates during the process of apoptosis before necrosis
(Hakuma ¨ki et al, 1999; Griffin et al, 2003). Correlations were also
found between apoptosis and the ca. 1.3p.p.m. (-CH2-) and ca.
0.9p.p.m. (-CH3) Lip/MM resonances in the non-necrotic biopsies
(Table 2 and Figure 3B), but the non-zero intercept indicates the
presence of additional ca. 1.3 and 0.9p.p.m. signals that do not
relate to apoptosis.
It has been suggested that apoptosis produces lipid bodies that
remain after cell death (Griffin et al, 2003), similar to those
observed with necrosis in rodent gliomas (Re ´my et al, 1997;
Lahrech et al, 2001; Zoula et al, 2003). However, in the necrotic
biopsies, we observed a correlation between the percentage of
necrosis and the ca. 2.8p.p.m. proton concentration (R¼0.663,
P¼0.0003, n¼25, data not shown), but no correlation was found
between the ca. 2.8p.p.m. peak and the number of TUNEL-positive
nuclei. This suggests that the ca. 2.8p.p.m. resonance in the
necrotic biopsies arises primarily from hypoxic/necrotic lipid
bodies rather than apoptotic lipid bodies. Overall, our data are in
agreement with earlier findings in animal studies that the PUFA
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Chemical shift (p.p.m.)
3.4
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Figure 4 HRMAS
1H MRS from a non-necrotic (top) and necrotic
(middle) biopsy showing the taurine and ca. 2.8p.p.m. Lip/MM contribu-
tions. The bottom spectrum is an in vitro taurine HRMAS
1H MR spectrum
showing the full taurine spectral pattern. Note that the biopsy spectra are
slightly shifted to the right for full view of the spectral peaks.
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Figure 5 Plots of TUNEL-positive nuclei per mm
2 against cell density
per mm
2 for non-necrotic (closed symbols, n¼14), necrotic astrocytoma
biopsies with a percentage necrosis o25% (large open symbols, n¼19)
and necrotic astrocytoma biopsies with a percentage necrosis 450% (small
open symbols, n¼6).
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speak at ca. 2.8p.p.m. originates during the process of apoptosis,
but our results (Figure 3A) suggest that this correlation is only true
for low-grade astrocytomas, which are non-necrotic.
A recent pattern recognition of HRMAS study of cervical
carcinoma biopsies (all except one being non-necrotic) has shown
that all the lipid peaks in the presaturation spectra contributed to
the principal components that correlated with the apoptotic cell
density, with a major contribution from the ratio of the
ca. 1.3p.p.m. to ca. 0.9p.p.m. Lip/MM peaks. Taurine was found
to be unrelated to apoptosis in these cervical carcinoma biopsies,
but instead related to the tumour cell density and tumour fraction
when combined with creatine, choline-containing metabolites,
glucose and lactate (Lyng et al, 2007). In our study, we did not find
any correlations between apoptosis (either the number of TUNEL-
positive nuclei per mm
2 or the apoptotic index (calculated as the
percentage of TUNEL-positive nuclei per cell density)), and the ca.
1.3p.p.m.:ca. 0.9p.p.m. Lip/MM ratios. Therefore, it appears that
biomarkers associated with apoptosis may be dependent on cancer
type.
Taurine concentrations have been shown to remain stable for up
to 8h in postmortem human brain (Perry et al, 1981), and we have
also recently shown taurine to remain stable in human brain
tumour biopsies (AS2 and GBM) and normal rat brain during
prolonged HRMAS spinning (Opstad et al, 2008c). Thus,
significant postischaemic changes in tumour biopsy taurine
concentrations as a result of the biopsy excision, and/or the
HRMAS procedure appear unlikely. Taurine is generally consi-
dered difficult to accurately measure in in vivo
1H MRS because of
signal overlap from the stronger signals of myo-inositol and the
cholines at E3.2p.p.m. and glucose at E3.4p.p.m. (Govindaraju
et al, 2000), with an exception being the observation of highly
elevated taurine in medulloblastomas (Moreno-Torres et al, 2004).
Generally, we would expect taurine editing, which has previously
been applied to in vivo
1H MRS of normal rat brain (Lei and
Peeling, 1999), would provide a more robust measurement of
taurine, and hence the use of taurine as an in vivo biomarker of
apoptosis (both pre- and posttherapeutic responses) for differing
grades of astrocytoma may be possible in the clinic.
In conclusion, we have shown that the taurine concentration in
astrocytomas correlates with the number of TUNEL-stained
apoptotic nuclei independently of the presence of necrosis. Our
data also suggest that taurine may be a better biomarker of
apoptosis in glial tumours than the ca 2.8p.p.m. PUFA peak, for
which a correlation with apoptosis is only found in non-necrotic
biopsies. These conclusions suggest that the measurement of
taurine in gliomas in vivo by non-invasive MRS could be a useful
technique for monitoring tumour apoptosis in the clinic.
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